Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results
FREMONT, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018 , as well as recent business highlights.
View HTML
Toggle Summary Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference
FREMONT, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will participate in a panel titled “Drug Delivery” to be held on Monday,
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update
FREMONT, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March 14, 2019 at 4:30 p.m. ET to discuss financial results for the fourth quarter
View HTML
Toggle Summary Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta™ for the Acute Treatment of Migraine Disease
Long-term one-year dosing reaffirmed well-tolerated safety profile Qtrypta showed robust and rapid relief of migraine pain, an effect that was consistent throughout the chronic treatment period NDA submission expected in Q4 2019 for the first intracutaneous delivery system FREMONT, Calif. , Feb.
View HTML
Toggle Summary Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines
FREMONT, Calif. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a post-hoc analysis of its pivotal Phase 2/3 (ZOTRIP) study in Headache: The Journal
View HTML
Toggle Summary Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
FREMONT, Calif. , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais , M.D., J.D. to its board of directors. Dr.
View HTML
Toggle Summary Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207
FREMONT, Calif. , Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has conditionally accepted the proposed brand name Qtrypta™ for
View HTML
Toggle Summary Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update
Selected a contract manufacturer for commercial launch of M207 Completed first required data set in long-term safety study of M207 Appointed Greg Kitchener as Chief Financial Officer FREMONT,Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update
FREMONT, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast to be held on Wednesday, November 14, 2018 at 4:30PM ET .
View HTML
Toggle Summary Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study
FREMONT, Calif. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150 evaluable subjects have completed their six month visit in the M207-ADAM study (the "Study"), a
View HTML